Name Change to: BioHarp & New Stock Symbol:Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp and will effectuate a new trading symbol and cusip number
No R/S and no raise to A/S:*The share structure of the company will remain in effect with no changes anticipated. We strongly feel that our Authorized shares at this time are sufficient to handle our merger and capital raise needs. We feel it would be disadvantageous to do any sort of reverse split due to the potential sales of the BioHarp unit in the coming years. If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we've received, the company's market cap will be substantial
Manufacturers announced: We also intend to secure the manufacturing relationships Mr. Lee has worked on over the past months in order to fulfill our needs for the BioHarp unit. Mr. Lee has identified several major manufacturers that can handle the volume of devices we'll need to fulfill the commitments we expect over the next 6-12 months and having strategic manufacturing partners in Korea to work closely with the technical staff is imperative to the success of the company.
Korean FDA approval announced:As for the KFDA process, Mr. lee has submitted the device for approval and due to his increased interest in making the device even better, has added an addendum to reflect the newest sensor him and the team worked on in the last several months. Upon my arrival in Korea, we will be going over all the KFDA applications and information so as to determine the next step for approval here in the US.
US FDA application submitted:In addition, our goal is to allow the KFDA to finalize their approval process and then take this approval and use it to speed up the process here for FDA Approval.
BioHarp sales announced to healthcare organizations and countries:We will market this product aggressively and have already been contacted by several countries in Asia and Europe that are interested in making the BioHarp part of their national healthcare program....The BioHarp unit market potential stretches globally. There has been interest from several health departments globally to deploy the BioHarp to outlying village areas and major metropolitan healthcare clinics to utilize the BioHarp as an effective tool for pre-diagnosis on regular physical appointments. These countries will use the five sensor unit and the software will be integrated into their respective national healthcare databases.
Uplisting to higher Exchange:Our goal is to move up to a greater exchange due to the potential sales that we anticipate the BioHarp will be doing globally very soon. We are working with our accountant and legal teams to ensure that we have everything in order so the migration to a higher exchange can be accomplished at the proper time.
Korean Stock Exchange Dual listing:While in Korea, XTend management will also be looking to secure a listing on the Korean Stock Exchange that will add to our shareholder base on a global basis and gain additional exposure for the company.
Deals announced in Pets/Veterinary Markets:The management at XTend has made several contacts with the veterinary market to utilize the BioHarp to scan dogs, cats, and other pets
Horse racing deals and contracts announced:The equine industry itself can be very lucrative for the company in the future. The management at XTend has several thoroughbred trainers and owners they have spoken with about utilizing the BioHarp as part of a daily routine for racehorses to insure their training and subsequent earnings potential is not compromised....there are literally hundreds of racetracks with thousands of horses, each representing a significant investment to their owners.These scans would be done with the one sensor unit and would probably be sold and managed by our internal medical team at BioHarp UNI US. The potential trainers and owners would contract with us to scan the animals regularly; generating daily, weekly, and/or a monthly maintenance fee schedule for the company
Marketing deals announced with medical device companies on a global scale:Our intention is to market the product aggressively throughout Asia, the U.S. and Europe. To date, we've had over 7 inquiries from medical device companies looking to represent the BioHarp in 4 different countries globally
Contracts with First Line Farmers: BioHarp can be used to detect cellular inflammation in plants. Diseases in crops have risen dramatically over the years and the BioHarp can assist scientists in helping to determine the proper course of treatment in order to insure plants can sustain life. The global percussion in this area can be tremendous for the company.
News 
Market Data 
Discover 
